Pages that link to "Q34090996"
Jump to navigation
Jump to search
The following pages link to Marimastat: the clinical development of a matrix metalloproteinase inhibitor (Q34090996):
Displaying 28 items.
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting (Q28298681) (← links)
- The role of myosin II in glioma invasion of the brain (Q30482874) (← links)
- Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro (Q30539235) (← links)
- Diorganotin(IV) derivatives of N-methyl p-fluorobenzo-hydroxamic acid: preparation, spectral characterization, X-ray diffraction studies and antitumor activity. (Q30656931) (← links)
- S100A4 and its role in metastasis – computational integration of data on biological networks (Q30977149) (← links)
- Matrix metalloproteinases in tumorigenesis: an evolving paradigm. (Q34199345) (← links)
- Exploring the role of mitochondrial UQCRB in angiogenesis using small molecules (Q34332044) (← links)
- Chemokine receptors: multifaceted therapeutic targets (Q34575325) (← links)
- Complex roles of tissue inhibitors of metalloproteinases in cancer (Q34596110) (← links)
- Exploiting molecular targets in pancreatic cancer (Q34684154) (← links)
- Antiangiogenic strategies, compounds, and early clinical results in breast cancer (Q35687692) (← links)
- Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness (Q35918449) (← links)
- BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. (Q37494812) (← links)
- Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. (Q37756119) (← links)
- New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. (Q38895520) (← links)
- Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation (Q40027116) (← links)
- Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori. (Q41008910) (← links)
- In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds (Q42231185) (← links)
- The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model (Q43963823) (← links)
- Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status (Q48567214) (← links)
- MMP inhibitor Ilomastat induced amoeboid-like motility via activation of the Rho signaling pathway in glioblastoma cells. (Q51771385) (← links)
- Alterations in the expression and activity of extracellular matrix components in HPV-associated infections and diseases (Q58699194) (← links)
- Hydroxamic Acids − An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands (Q60328312) (← links)
- Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors (Q83534480) (← links)
- Vascularized Microfluidics and the Blood-Endothelium Interface (Q92257481) (← links)
- Direct N-O bond formation via oxidation of amines with benzoyl peroxide (Q92431503) (← links)
- Matrix metalloproteinases in keratinocyte carcinomas (Q99637911) (← links)
- The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus (Q104073695) (← links)